Skip to main content
Fig. 4 | BMC Complementary and Alternative Medicine

Fig. 4

From: Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease

Fig. 4

Effects of combination treatment on days 1 (a), 3 (b), 5 (c), and 7 (d) after first treatment with KD5040 based on the pole test. KD5040 in combination with l -dopa (LL and ML) reduced time to descend compared to the respective doses of l -dopa alone. C: control, M: MPTP, K: KD5040, LL: low dose of l -dopa (5 mg/kg), ML: medium dose of l -dopa (10 mg/kg). *** p < 0.001, ** p < 0.01, and * p < 0.05 vs. control, ### p < 0.001, ## p < 0.01, and # p < 0.05 vs. MPTP, and ††† p < 0.001, †† p < 0.01, and † p < 0.05 vs. each dose of l -dopa

Back to article page
\